A study shows is that the new treatment of mesothelioma possible

A new study called cold plasma coagulation in the treatment of malignant pleural mesothelioma: Results of a combined approach was published in Interactive Cardiovascular, and Thoracic Surgery, an online journal. The study describes a new practice to the test by a group of researchers tried to increase the effectiveness of the treatment of mesothelioma.

Mesothelioma, a terminal cancer through inhalation or ingestion of asbestos fibers caused the death of ten months after diagnosis of eighteen years, on average. The disease can take decades to develop from the time of first exposure to asbestos fibers, lending his diagnosis difficult and help that most patients have advanced stage before the start of treatment. Due to the long latency period of the disease, the diagnosis should increase each year after 2015, although tightening a ban on asbestos and regulations continue.

Mesothelioma, a malignant tumor or soft tissue called mesothelium, is a palliative treatment, this treatment was developed to increase convenience for patients and prolong their survival in the supply of any medicine means. The vast majority of patients with mesothelioma subject of a combination of chemotherapy, surgery and radiation therapy.

In recent years a technique known as the heated chemotherapy has shown promise in patients, the surgical resection. The procedure involves washing the affected tissue in a solution of chemotherapy hot, the heat increases the absorption effectively destroy cancer cells missed by surgery. heated chemotherapy makes threats, but also damage to the diaphragm and the pericardium C envelope of the heart.

The new method of mesothelioma treatment has been tested cold-plasma coagulation in patients with stage III mesothelioma. Stage III describes the state of the disease if the malignancy has spread beyond the original tumor to the lymph nodes more. Cold-plasma coagulation is used to destroy malignant tissues and cells of the pleura, diaphragm and pericardium in a regular chemotherapy treatment was applied heated. The results, say the researchers, proved to be as safe as the pre-treatment methods and can be a useful addition to multimodal therapy in the future.

The study's authors were careful in their statements, declaring that further testing may be necessary to draw conclusions.

We believe that our vision of a pilot study, they said, to evaluate the potential benefits of using the survival of these] [Cold Plasma Technology, larger studies are needed.